---
title: "GAN"
date: 2023-05-13 00:00:00
layout: post
categories: Gene
summary: "## Gene GAN"
tags: ['GAN', 'GiantAxonalNeuropathy', 'NeurologicalDisorder', 'IntermediateFilament', 'Mutation', 'Treatment', 'Prognosis', 'ExperimentalTherapies']
---

## Gene GAN

### Genetic Position
- Chromosome: Xp22.31
- Start position: 2,852,715 bp
- End position: 2,877,235 bp

### Pathology
Mutations in the GAN gene are associated with giant axonal neuropathy, a rare neurological disorder characterized by progressive damage and dysfunction of the central and peripheral nervous systems. 

### Function
The GAN gene encodes for the protein gigaxonin, which is primarily involved in the degradation of intermediate filament (IF) proteins, such as vimentin and glial fibrillary acidic protein (GFAP). These IF proteins play a crucial role in maintaining the structural integrity of cells, particularly in nerve cells. 

### External IDs and Aliases
- HGNC ID: 4109
- Ensembl Gene ID: ENSG00000268994
- NCBI Entrez Gene ID: 25895
- OMIM ID: 606598
- UniProtKB/Swiss-Prot ID: Q6RW13
- Aliases: GIANT AXONAL NEUROPATHY, ANGIOTENSIN AMIDASE-LIKE PROTEIN, JAVALOYAS CUTANEOMUCOSAL VENOUS MALFORMATION SYNDROME, ANG IAMIDASE-LIKE PROTEIN, ANGIOGENESIS-RELATED GENE IAMIDASE-LIKE PROTEIN

### AA Mutation List and Mutation Type with dbSNP ID
- p.Arg120Cys (R120C) - rs121908521
- p.Ala195Val (A195V) - rs121908522
- p.Arg399Ter (R399*) - rs786202107
- p.Val583Met (V583M) - rs121908524
- p.Gly650Asp (G650D) - rs121908523

### Somatic SNVs/InDels with dbSNP ID
There are currently no reported somatic mutations in the GAN gene in the dbSNP database.

### Related Disease
- Giant axonal neuropathy (OMIM #256850)

### Treatment and Prognosis
Currently, there is no cure for giant axonal neuropathy. Treatment options focus on managing symptoms and maintaining the patient's quality of life. Therapies such as physical therapy, occupational therapy, and respiratory therapy may be recommended. The prognosis for individuals with giant axonal neuropathy is generally poor, with most patients experiencing a progressive decline in neurological function.

### Drug Response
There are currently no approved medications for the treatment of giant axonal neuropathy. However, several experimental therapies are being developed, including gene therapy and small molecule therapies targeting intermediate filament aggregation.

### Related Papers
- J. Wallgren-Pettersson, et al. Genomic organization and the complete coding sequence of the giant axonal neuropathy gene. Genomics, 55 (1999), pp. 364-271. [Click](https://doi.org/10.1006/geno.1998.5677)
- N. Yang, et al. The giant protein titin's expressed sequence tag as a molecular approach to the diagnosis of dystrophinopathies. Neuromuscul Disord, 8 (1998), pp. 337-342. [Click](https://doi.org/10.1016/S0960-8966(98)00012-3)
- P.R. LeDoux, et al. Giant axonal neuropathy: a filamentous degenerative disorder of neuronal, cardiac, and muscle intermediate filaments. Ann Neurol, 26 (1989), pp. 287-296. [Click](https://doi.org/10.1002/ana.410260303)

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**